Roche's Genen­tech goes on deal spree, un­veil­ing third deal on the same day

The busi­ness de­vel­op­ment ex­ec­u­tives at Roche’s Genen­tech have been busy shop­ping.

Af­ter an­nounc­ing tie-ups with So­sei Hep­tares and Sky­hawk on Tues­day, Genen­tech un­veiled yet an­oth­er deal: with Cleve­land-based biotech Con­velo Ther­a­peu­tics.

The com­pa­ny, found­ed in 2016 by Case West­ern Re­serve Uni­ver­si­ty School of Med­i­cine pro­fes­sors, has been en­list­ed to help Genen­tech de­vel­op med­i­cines with neu­ro­log­i­cal dis­or­ders such as mul­ti­ple scle­ro­sis. The Roche com­pa­ny al­ready sells the in­tra­venous ther­a­py Ocre­vus, which was ap­proved for re­laps­ing forms of mul­ti­ple scle­ro­sis as well as pri­ma­ry pro­gres­sive mul­ti­ple scle­ro­sis in 2017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.